Page 21 - Read Online

Manrique et al. Microbiome Res Rep 2024;3:23 https://dx.doi.org/10.20517/mrr.2023.80 Page 15 of 20

exopolysaccharides. Appl Microbiol Biotechnol 2016;100:1121-35. DOI PubMed
3. Bron PA, Kleerebezem M. Engineering lactic acid bacteria for increased industrial functionality. Bioeng Bugs 2011;2:80-7. DOI
PubMed
4. Baeshen MN, Al-Hejin AM, Bora RS, et al. Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J
Microbiol Biotechnol 2015;25:953-62. DOI
5. Kostic AD, Howitt MR, Garrett WS. Exploring host-microbiota interactions in animal models and humans. Genes Dev 2013;27:701-
18. DOI PubMed PMC
6. Patterson E, Cryan JF, Fitzgerald GF, Ross RP, Dinan TG, Stanton C. Gut microbiota, the pharmabiotics they produce and host
health. Proc Nutr Soc 2014;73:477-89. DOI PubMed
7. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330-9. DOI
PubMed PMC
8. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age,
environment, diet, and diseases. Microorganisms 2019;7:14. DOI PubMed PMC
9. Cheng L, Qi C, Zhuang H, Fu T, Zhang X. gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders
and interventions. Nucleic Acids Res 2020;48:7603. DOI PubMed PMC
10. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis
2015;26:26191. PubMed PMC
11. Wilkins LJ, Monga M, Miller AW. Defining dysbiosis for a cluster of chronic diseases. Sci Rep 2019;9:12918. DOI PubMed PMC
12. Green JE, Davis JA, Berk M, et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than
Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes 2020;12:1-25. DOI PubMed PMC
13. Mehta P, Nahass RG, Brunetti L. Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides
difficile infection: systematic review and meta-analysis. Clin Infect Dis 2021;73:e62-8. DOI PubMed PMC
14. Sorbara MT, Pamer EG. Microbiome-based therapeutics. Nat Rev Microbiol 2022;20:365-80. DOI PubMed
15. Alam MZ, Maslanka JR, Abt MC. Immunological consequences of microbiome-based therapeutics. Front Immunol
2023;13:1046472. DOI PubMed PMC
16. Gulliver EL, Young RB, Chonwerawong M, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol
Ther 2022;56:192-208. DOI PubMed PMC
17. Manrique P, Dills M, Young MJ. The human gut phage community and its implications for health and disease. Viruses 2017;9:141.
DOI PubMed PMC
18. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022;7:135. DOI PubMed PMC
19. Miller CP, Bohnhoff M, Rifkind D. The effect of an antibiotic on the susceptibility of the mouse’s intestinal tract to salmonella
infection. Trans Am Clin Climatol Assoc 1956;68:51-5; discussion 55-8. PubMed
20. Maciel-Fiuza MF, Muller GC, Campos DMS, et al. Role of gut microbiota in infectious and inflammatory diseases. Front Microbiol
2023;14:1098386. DOI PubMed PMC
21. Liu P, Lu Y, Li R, Chen X. Use of probiotic lactobacilli in the treatment of vaginal infections: in vitro and in vivo investigations.
Front Cell Infect Microbiol 2023;13:1153894. DOI PubMed PMC
22. Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis.
Nat Med 2019;25:1500-4. DOI
23. Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J
Hematol Oncol 2022;15:47. DOI PubMed PMC
24. Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New insights into the cancer-microbiome-immune axis: decrypting a decade of
discoveries. Front Immunol 2021;12:622064. DOI PubMed PMC
25. Ağagündüz D, Cocozza E, Cemali Ö, et al. Understanding the role of the gut microbiome in gastrointestinal cancer: a review. Front
Pharmacol 2023;14:1130562. DOI PubMed PMC
26. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science
2015;350:1079-84. DOI PubMed PMC
27. Hamada K, Yoshimura K, Hirasawa Y, et al. Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer
patients on anti-PD-1 immunotherapy. Anticancer Res 2021;41:4985-93. DOI
28. Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma
patients. Science 2021;371:595-602. DOI PubMed PMC
29. Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory
melanoma patients. Science 2021;371:602-9. DOI
30. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Science 2015;350:1084-9. DOI PubMed PMC
31. Routy B, Lenehan JG, Miller WH Jr, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a
phase I trial. Nat Med 2023;29:2121-32. DOI PubMed
32. Tanoue T, Morita S, Plichta DR, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature
2019;565:600-5. DOI
33. Scheline RR. Drug metabolism by intestinal microorganisms. J Pharm Sci 1968;57:2021-37. DOI PubMed